Oncology is the largest, fastest-growing, and most commercially competitive therapeutic area in pharmaceuticals. Global oncology drug revenues exceeded $300 billion in 2025 and are growing at approximately 12% annually. Keytruda alone at $31.7 billion generates more annual revenue than the entire pharmaceutical markets of most individual countries.

The transformation of cancer treatment has been driven by three converging forces. Immune checkpoint inhibitors have become standard of care across more than twenty cancer types. Targeted therapies guided by companion diagnostics are delivering progression-free survival benefits in biomarker-defined patient populations. And antibody-drug conjugates are combining the targeting precision of monoclonal antibodies with the cell-killing power of cytotoxic payloads, demonstrating activity across tumor types defined by target expression rather than histology alone.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Topics Covered
• Immune Checkpoint Inhibitors
• Targeted Therapy
• Antibody-Drug Conjugates
• CAR-T and Cell Therapy
• Radiopharmaceuticals
• Bispecific Antibodies
• Liquid Biopsy and Precision Oncology